Lumexa Imaging, formerly known as US Radiology Specialists, has filed with the SEC to go public and is set to raise as much ...

After laying off 80% of staffers this spring, Tempest Therapeutics is acquiring several CAR-T programs from Factor Bioscience ...

Precise Bio has reported the first successful human implantation of its 3D-printed cornea implant, constructed of functional ...

Korea’s Celltrion is continuing to think bigger than biosmilars, this time securing the option to use TriOar’s antibody ...

Merck & Co. has reported another phase 3 win for islatravir in HIV, advancing its efforts to establish the near-approval ...

“Under Belgian rules, you can't really do that because it takes a 75% vote,” Gosebruch explained. “Gilead owns 25% and ...

As the biopharma world predominantly zeroes in on late-stage assets, Eli Lilly is prioritizing early science with the opening ...

Dexcom has obtained an FDA clearance for its basal insulin dosing optimizing program, designed for adults with Type 2 diabetes using its continuous glucose monitors.  | Dexcom said Smart Basal is the ...

GSK has paid $50 million upfront to partner with LTZ Therapeutics on myeloid cell engagers, expanding its cancer pipeline to cover a modality that has attracted Eli Lilly, Novartis, Pfizer and Sanofi.

Cytokinetics may be counting down the days until the FDA decides whether to approve its cardiovascular drug aficamten. | ...

The investment bank Jefferies had been running its healthcare conference in London for 14 years as a reasonably intimate ...

Vanda Pharmaceuticals’ expansion into the booming GLP-1 market has cleared a midphase test. | Vanda Pharmaceuticals’ ...